Alliance meets with leaders on Capitol Hill
Representatives from the Colorectal Cancer Alliance met with congressional officials on Capitol Hill this week to gain support for colorectal cancer (CRC) research, urging immediate action to address the devastating toll of CRC on Americans.
The meetings are part of a broader government advocacy initiative by the Alliance to address the growing prevalence of CRC and improve patient care, advance research, and break down regulatory barriers that limit access to life-saving treatments.
The efforts of the Alliance will focus on the importance of CRC funding and regulatory reform with these key priorities:
- Address funding disparities by increasing colorectal cancer funding at the National Cancer Institute (NCI) and $20 million within the Congressionally Directed Medical Research Program (CDMRP)
- Address regulatory barriers that inhibit all Americans from receiving quality care for colorectal cancer, including expanding access to biomarker testing
- Improve screening technologies and recommendations for colorectal cancer
The Alliance is committed to ensuring that colorectal cancer remains a national priority. By advocating for increased funding, regulatory improvements, and access to innovative treatments, we can save lives and improve patient outcomes. Now is the time for policymakers to act.
Top resources
FDA Clears Way for Colorectal Cancer Clinical Trial Led by Dr. Christopher Lieu
The U.S. Food and Drug Administration has given researchers at the University of Colorado Anschutz Medical Campus permission to begin a clinical trial of CAR T-cell therapy for people with advanced colorectal cancer who have already tried the standard treatments without lasting success.
He almost skipped the colonoscopy that saved his life
Andy said his lifestyle made it easier to ignore the blood in the stool, a symptom of colorectal cancer. But the “mirage of invincibility,” as he called it, was about to vanish.
Alliance Appoints New Members to Board of Directors
Each of the four appointees to the Alliance's Board brings unique professional expertise and a personal commitment to the organization's mission to end colorectal cancer in our lifetime.